Healthcare | August 02, 2021
Krsnaa Diagnostics public issue opens from Aug 4-6th 2021
Price band in the range of Rs 933 to Rs 954
Price band in the range of Rs 933 to Rs 954
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has already embarked upon significant expansion in Turkey
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Subscribe To Our Newsletter & Stay Updated
